The International Liver Congress 2009, 44th Annual Meeting of the European Association for the Study of the Liver (EASL), is taking place in Copenhagen, Denmark, 22󈞆 April 2009. The official website is: http://www.easl.eu. Over 7,000 clinicians and scientists are expected to attend EASL 2009. Over the course of the Meeting, 144 oral presentations and 199 posters drawn from over 2179 abstract submissions will be featured.

2009 Annual Meeting of the European Association for the Study of the Liver*

April 22-26, 2009 | Copenhagen, Denmark

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

http://www.clinicaloptions.com

From NATAP

EASL: EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 �g/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE 1 PATIENTS - IMPACT Of CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY - (05/14/09)

EASL: EASL Analysis, New Oral HCV Drugs What's Expected - (05/14/09)

EASL: Histologic Outcomes in Hepatitis C-Infected Patients With Breakthrough or Relapse to Interferon-Based Treatments: there was a positive correclation between viral response and improved fibrosis - (05/13/09)

EASL: BASELINE CHARACTERISTICS AND WEEK 4 RESPONSE AMONG CHRONIC HEPATITIS C PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 OR 4: INTERIM RESULTS OF THE PROPHESYS TRIAL - (05/13/09)

EASL: Identifying Patients Infected With HCV Genotype 1 Who May Benefit From Extended Peginterferon Alfa-2a/Ribavirin Therapy Beyond 48 Weeks - (05/13/09)

EASL: IDENTIFYING PATIENTS WITH A HIGH LIKELIHOOD OF ACHIEVING AN SVR FOLLOWING RE-TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN: USE OF POSITIVE PROGNOSTIC FACTORS (PPF'S) - (05/12/09)

EASL: Ursodeoxychic Acid Improved NASH, Not So Sure About Rosiglitazone - (05/12/09)

EASL: Single and Multiple-Dose Assessments of the Safety and Pharmacokinetics of SCH 900518 and Its Effect on the Pharmacokinetics of Midazolam in Healthy Subjects - (05/12/09)

EASL: Preclinical Characterization of SCH 900518,A Novel Mechanism-Based Inhibitor of HCV NS3 Protease - (05/12/09)

EASL: Individualized treatment duration with peginterferon alfa-2b and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (INDIV-2 study) - (05/12/09)

EASL: A Regional Gastrointestinal Absorption Study of the HCV NS3 Protease Inhibitor SCH 900518 in Healthy Volunteers: "remote-controlled drug delivery device that delivers any form of drug to key regions of the human gastrointestinal (GI) tract." - (05/12/09)

EASL: Preclinical Pharmacokinetic and Safety Profile of IDX375, A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor - (05/11/09)

EASL: Preclinical Profiles of IDX136 and IDX316, Two Novel Macrocyclic HCV Protease Inhibitors - (05/11/09

EASL: IDENTIFICATION AND PROFILE OF POTENT AND SELECTIVE INHIBITORS OF HCV NS5A PROTEIN - (05/11/09)

Phase 2a Study to Evaluate the Safety and Tolerability and Anti-Viral Effect of 4 Doses of a Novel, Controlled-Release Interferon Alfa-2b (LocteronTM) Given Every 2 Weeks for 12 Weeks in Treatment-Naive Patients with Chronic Hepatitis C (Genotype 1) (AASLD 2007) - (05/08/09)

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection...PROVE1 in NEJM 4/2009 - (05/08/09)

EASL: Albuferon vs Pegasys Genotype 2/3 - (05/07/09)

EASL: Albuferon vs Pegasys Genotype 1 - (05/07/09)

EASL: Co Press Release: Biolex presents Locteron US Phase 2a hepatitis C data at EASL - (05/07/09)

EASL: Identification and Characterization of VCH-222, a Novel Potent and Selective Non-Nucleoside HCV Polymerase Inhibitor - (05/07/09)

EASL: Activity & Genotypic and Phenotypic Analysis of HCV NS5B Variants Selected from Patients Treated with VCH-916 - (05/07/09)

EASL: Randomized Trial Comparing Systemic and Local Reactions to Controlled-release Interferon Alpha2b and Pegylated-interferon Alpha2b in Hepatitis C Patients Who Failed Prior Treatment - (05/07/09)

EASL: Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide with Peginterferon Alfa-2a and Ribavirin in Nonresponders (NR) with Chronic HCV Genotype 1: Week 28 Interim Analysis - (05/07/09)

EASL: Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in HCV Genotype 1 Naïve Patients: Interim Analysis Shows Increase in EVR - (05/07/09)

EASL: Preclinical Pharmacokinetic and ADME Characterization of VCH-222, a Novel Non-Nucleoside HCV NS5B Polymerase Inhibitor from Vertex/ViroChem - (05/07/09)

EASL: IDX184, A Liver-Targeted Nucleotide HCV Polymerase Inhibitor: Results of a First-in-Man Safety and Pharmacokinetic Study - (05/07/09)

EASL: Antiviral Activity of the Liver-Targeted Nucleotide HCV Polymerase Inhibitor IDX184 Correlates with Trough Serum Levels of the Nucleoside Metabolite in HCV-infected Chimpanzees - (05/07/09)

EASL: Albuferon vs Pegasys Genotype 1 - (05/06/09)

EASL: Pharmacokinetics, Safety and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Multiple Ascending Doses and Effect of Co-Administration of Ketoconazole in Healthy Subjects - (05/06/09)

EASL: Characterization of Resistance Mutations Selected In Vitro by Non-Nucleoside HCV Polymerase Inhibitors ABT-333 and ABT-072

EASL: Characterization of Resistance Mutations Selected In Vitro by Non-Nucleoside HCV Polymerase Inhibitors ABT-333 and ABT-072 - (05/06/09)

EASL: US Hepatitis C Burden Assessment from a Transmission Model: HCV burden reduced by new HCV drugs - (05/06/09)

EASL: Pharmacokinetics and Tolerability of the HCV Polymerase Inhibitor ABT-333 Following Single Ascending Doses in Healthy Adult Volunteers - (05/06/09)

EASL: Safety, Tolerability and Pharmacokinetics of the HCV Polymerase Inhibitor VCH-222 Following Single Dose Administration in Healthy Volunteers and Antiviral Activity in HCV-infected Individuals - (05/06/09)

EASL: Safety, Tolerability, and Pharmacokinetics of GS-9450 in Healthy Male and Female Volunteers - (05/05/09)

EASL: Abbott/Enanta - Potent HCV Protease Inhibitors with the Potential for Once-daily Dosing and Broad Genotype Coverage - (05/05/09)

EASL: Preclinical Characterization of ABT-072: A Novel Non-Nucleoside HCV Polymerase Inhibitor - (05/05/09)

EASL: Preclinical Potency, Pharmacokinetic and ADME Characterization of ABT-333, A Novel Non-Nucleoside HCV Polymerase Inhibitor - (05/05/09

EASL: 2 Schering HCV Protease Inhibitors; Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

EASL: EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS

EASL: SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS

EASL: PegIntron Maintenance Therapy in Cirrhotic (METAVIR F4) HCV Patients Who Failed to Respond to Interferon/Ribavirin (IR) Therapy: Final Results of the EPIC3 Cirrhosis Maintenance Trial

Recombinant (EPO) human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

EASL: HCV SPRINT-1: Final Results SVR 24 NS3 Protease Inhibitor Boceprevir plus PegIFN alpha-2b/Ribavirin HCV 1 Treatment Naïve Patients -

SL: Antiviral Activity and Safety of ITMN-191 (R7227) in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus

EASL: HCV SPRINT-1: Final Results SVR 24 NS3 Protease Inhibitor Boceprevir plus PegIFN alpha-2b/Ribavirin HCV 1 Treatment Naïve Patients - (04/30/09)

EASL: Antiviral Activity and Safety of ITMN-191 (R7227) in Combination with Peginterferon alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Virus - (04/29/09)

EASL: Antiviral activity and safety of TMC435 combined with peginterferon a-2a and ribavirin in patients with genotype-1 hepatitis C infection who failed previous IFN-based therapy - (04/29/09)

EASL: Antiviral Activity of Filibuvir in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days in Treatment-Naive Patients Chronically Infected with HCV Genotype 1 - (04/29/09)

EASL: Subgroup Analysis Confirms Efficacy, Safety of Sorafenib in Patients With Late-Stage Liver Cancer: Presented at EASL - (04/29/09)

EASL: A FIRST CLINICAL TRIAL OF THERAPEUTIC VACCINATION USING NAKED DNA DELIVERED BY IN VIVO ELECTROPORATION SHOWS ANTIVIRAL EFFECTS IN PATIENTS WITH CHRONIC HEPATITIS C - (04/29/09)

EASL: Safety, Tolerability, and Pharmacokinetics after Single and Multiple Doses of MK-3281 in Healthy Subjects - (04/28/09)

EASL: MK-7009 Significantly Improves Rapid Viral Response (RVR) in Combination with Pegylated Interferon Alfa-2a and Ribavirinin Patients with Chronic Hepatitis C (CHC) Genotype 1 Infection - (04/28/09)

EASL: Metabolic Syndrome Hikes Mortality in Hepatitis C - (04/28/09)

EASL: Ground-Breaking Combination of 2 All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen (ITMN-191 protease + R7128 NRTI) - (04/28/09)

EASL: FDA Regulations for HCV Drug Development - are they too Strict? - (04/28/09)

EASL: Can Peginterferon and Ribavirin Be Eliminated from Therapy - (04/28/09)

EASL: Roche and Pharmasset start phase IIb clinical trial of R7128 nucleoside polymerase inhibitor for chronic hepatitis C - (04/28/09)

EASL: OPERA-1 trial (Study TMC435-C201): interim analysis of safety and antiviral activity of TMC435 in treatment-naÏve genotype-1 HCV patients - (04/28/09)

EASL: TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY - (04/28/09)

EASL: Potent Antiviral Activity With A Nucleoside Polymerase (R7128) And Protease (R7227/ITMN-191) Inhibitor Combination in HCV Genotype 1: Initial Safety, Pharmacokinetics, And Virologic Results From INFORM-1 - (04/28/09)

EASL: EASL Day 3 Saturday - (04/28/09)

EASL: HCV Protease ITMN-191 + Peg/RBV for 14 Days - safety, antiviral activity - (04/28/09)

EASL: SCH-900518 New Schering Protease Inhibitor Monotherapy & with Peg/RBV 7-14 days - (04/28/09)

EASL: Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C - (04/28/09)

EASL: Peg-Interferon lambda + Ribavirin 4 Weeks - (04/28/09)

EASL: Telaprevir Effective for Genotype 2 But Not For Genotype 3 - (04/27/09)

EASL: Maintenance Therapy: we don't know if it provides benefit - (04/27/09)

EASL: HIV positive and HIV negative patients have similar survival rates following liver transplant - (04/27/09)

EASL: Anadys shares plunge on hepatitis C drug ANA598 safety concerns - (04/27/09)

EASL: Schering's protease boceprevir phase 2; Schering symposium - (04/27/09)

EASL: Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days' oral treatment in patients with chronic hepatitis C - (04/27/09)

EASL: ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients - (04/24/09)

EASL: Tibotec HCV Protease TMC435 I Treatment-Naives Genotype 1, Monotherapy & Combination with Peg/RBV - (04/24/09)

EASL: New HCV Drugs II: Schering's protease boceprevir phase 2; Abbott/Enanta HCV Protease Inhibitors; Progenics PRO-206 HCV Entry Inhibitor - (04/24/09)

EASL: Taribavirin vs Ribavirin - (04/24/09)

EASL: New HCV Drugs Today at EASL 1st Day - (04/24/09)

EASL: EASL New HCV Drugs - (04/23/09)

EASL: EPIC Study Shows Maintenance Therapy Provides Benefits -

Low-Dose Naltrexone Eases Pain and Fatigue of Fibromyalgia - (04/22/09)

Metabolic Syndrome Hikes Mortality in Hepatitis C

By John Gever, Senior Editor, MedPage Today

March 2009

13th International Symposium on Viral Hepatitis and Liver Disease
March 20-24, 2009
Washington, DC

HCV Vaccine Development

Pegylated Interferon Monotherapy for Treatment of Chronic Hepatitis B

ImQuest Identifies First Non-nucleoside Inhibitors of Hepatitis B Virus

Studies Shed More Light on Acute Hepatitis C among HIV Positive Men in the U.S. and Europe

Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C

ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C. -

TMC435 HCV Protease Inhibitor Safety/antiviral activity OPERA Study doses 25 & 75 mg once daily -

Screening for Acute Hepatitis C Virus Infection (AHCV) among At-Risk Patients in an HIV Clinic -

Treatment for Hepatitis B: When to Start, What to Use, and When to Stop

Chronic Hepatitis B Patients May Need to Begin Liver Cancer Screening at a Younger Age than Currently Recommended

HCV Reinfection and Superinfection Are Common among Injection Drug Users

Safety and antiviral activity of TMC435 (TMC435350) in treatment-naïve genotype 1 HCV-infected patients Study TMC435-C201

Variables Impacting Treatment and Prognosis in Young Patients(under Age 40) who Develop Hepatitis B Virus-Associated Hepatocellular Carcinoma; Implications for Management of an Unscreened Population

Many Asian-American Primary Care Providers Do Not Screen their Asian-American Patients Who Are at Risk for Chronic Hepatitis B

Tenofovir (Viread) during Pregnancy: Findings from the Antiretroviral Pregnancy Registry

Abstracts

The abstracts for the 13th International Symposium on Viral Hepatitis and Liver Disease are now available.

Download – Oral Abstracts for Saturday, March 21

Download – Oral Abstracts for Sunday, March 22

Download – Oral Abstracts for Monday, March 23

Download – Oral Abstracts for Tuesday, March 24

Download – Poster Presentation Abstracts

Download – Invited Speaker Abstracts

Also See:
HIV and Hepatitis.com Coverage of the
13th International Symposium on Viral
Hepatitis and Liver Disease (ISVHLD 2009)
March 20 - 24, 2009, Washington, DC

Sept 2008

Join Or Visit Our Message Boards For Coverage

AASLD/EASL/DDW CONFERENCE NEWS

Coverage Can Be Found At The Following Sites:

Conference Reports for NATAP

From: HIV and Hepatitis.com Coverage

Liver Disease Progression and Treatment Response in Latino and Asian Patients with Chronic Hepatitis C - 12/12/2008
Silibinin Milk Thistle Extract Demonstrates Antiviral Activity in Non-responders to Interferon-based Therapy for Chronic Hepatitis C - 12/12/2008
SAMe Improves Early Response to Pegylated Interferon/ribavirin in Small Study - 12/12/2008
Is Maintenance Therapy with Pegylated Interferon Monotherapy Ineffective-or Even Harmful to Patients? - 12/12/2008
Long-term Low-dose Pegylated Interferon May Improve Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders - 12/08/2008
Results of the IDEAL Study of Treatment of African Americans with Chronic Hepatitis C: A Slide Set Review - 12/082008
CD4 T-cell Responses to HCV during and after Interferon-based Therapy for Chronic Hepatitis C - 12/05/2008
Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents - 12/02/2008
Prodrug Taribavirin Produces Equivalent Response, but Less Anemia than Ribavirin at 48 Weeks - 12/02/2008
Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers - 11/25/2008
Three New STAT-C Agents Show Promise in Preclinical Studies and Early Clinical Trials: MK-7009, ANA598, and IDX375 - 11/25/2008
Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients - 11/21/2008
Canadian POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated Interferon plus Ribavirin - 11/21/2008
Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin - 11/18/2008
Sexual Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based Therapy for Chronic Hepatitis C - 11/14/2008
HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers - 11/14/2008
HCV Protease Inhibitor ITMN-191 (R7227) Demonstrates Antiviral Potency in Genotype 1 Patients; New ITMN-5489 Also Under Study - 11/14/2008
R7128 plus ITMN-191 Perform Well in Laboratory Study; STAT-C Combination Clinical Trial Now Underway - 11/14/2008
HCV Protease Inhibitor Telaprevir (VX-950) Continues to Perform Well in PROVE Trials - 11/11/2008
Experimental HCV Protease Inhibitor TMC435350 Demonstrates Favorable Safety and Efficacy in Phase 2a Trial - 11/11/2008
Investigational HCV Protease Inhibitor BI 201335 Exhibits Promising Antiviral Activity - 11/11/2008
HCV Polymerase Inhibitor PF-00868554 Inhibits Viral Replication in Treatment-naive Patients - 11/11/2008
IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia - 11/07/2008
Several “STAT-C” Agents Discussed at the Liver Meeting - 11/07/2008
HCV Protease Inhibitor Boceprevir plus Pegylated Interferon/Ribavirin Increases Sustained Virological Response Rate: SPRINT-1 Study - 11/04/2008

May-April 2008

HIV and Hepatitis.com Coverage of
DIGESTIVE DISEASE WEEK (DDW 2008)
May 17 - 22, 2008, San Diego, California

Janis and Friends Forum: Read and Comment on EASL& DDW Coverage.

Conference Reports from NATAP

HIV and Hepatitis.com

Coverage of the
43^rd EASL Conference (EASL 2008)
April 23 - 27, 2008, Milan Italy

Nov 2007

HIV and Hepatitis.com Coverage of the
58th Annual Meeting of the American Association
for the Study of Liver Diseases (AASLD 2007)
November 2-6, 2007, Boston, MA

HCV Advocate’s AASLD Conference coverage

Welcome to the HCV Advocate’s AASLD Conference coverage. In an effort to best serve our readership, we will post all the important and interesting abstracts about HCV from the conference. While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted.

http://www.hcvadvocate.org/news/reports/AASLD_2007/AASLD%202007%20TOC.htm

APRIL 2007

NATP

coverage of:

EASL
42nd European Association for the Study of Liver Diseases
Barcelona, Spain
April 11-15, 2007

42nd EASL
April 11 - 15, 2007
Barcelona, Spain

THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

November 2006

Coverage of 57th Annual Meeting of the American Association for the Study of Liver Disease

Oct 27-31,2006, Boston MA

NATAP

http://www.natap.org/

HCV Advocate

AASLD 2006 Onsite Coverage

May 2006

HIV and Hepatitis.com

Coverage of
Digestive Disease Week 2006

(DDW 2006)
May 20 - 25, 2006, Los Angeles, California

DDW 2006
Main Page

HIV and Hepatitis.com
Coverage of the

41st Annual Meeting of the
European Association for
the Studyof the Liver
(41st EASL)
April 26 - 30, 2006,
Vienna, Austria

Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week 2006 (DDW 2006) 37th Annual Meeting in Los Angeles

From Janis and Friends:

AASLD CONFERENCE NEWS

Nov 11 - 15, 2005 San Francisco, CA

Join our Forum in order to discuss the AASLD

click below and enter as our guest to read the conference news

Chat Room & Message Boards

HIVandHepatitis.com Coverage of Highlights from the

56th Annual Meeting of the American Association for the
Study of Liver Diseases
Nov 11 - 15, 2005 San Francisco, CA

HCV Advocate’s AASLD Conference coverage

http://www.hcvadvocate.org/news/reports/AASLD_2005/TOC_AASLD_2005_HCV.htm

From Janis and Friends:

May 14 - 19, 2005

Digestive Disease Week 2005 (DDW 2005)

DDW 2005 CONFERENCE NEWS

From HIV and Hepatitis :

Highlights from
Digestive Disease Week 2005 (DDW 2005)
May 14 - 19, 2005, Chicago, IL

From HCV Advocate :

DDW 2005

From Janis and Friends:

April 13-17 2005

40th Annual meeting of the European Association for the Study of the Liver

(40th EASL)

2005 40th EASL

From HIV and Hepatitis :

Highlights from the
40th Annual meeting of the European Association for the Study of the Liver (40th EASL)
April 13 - 17, 2005, Paris, France

Highlights from the
1st European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-infected Patients
March 1-2, 2005, Paris, France

AASLD 2004 Research Conferences

Oct 29- Nov 1 2004 Research Conferences

Our message boards have the latest reports coming out of the AASLD . Here you can also comment on the research.

From Janis and Friends :AASLD 2004 & CONFERENCES DATA

HIVandHepatitis.com and HCVAdvocate.org are the best sites for the AASLD 2004 Research Conferences .

Clicking below will take you away from our site, click on your back button to return to Janis and Friends

From HIVandHepatitis.com :

55^th Annual Meeting of the American Society for the Study of Liver Diseases (55th AASLD)
October 29 - November 2, 2004, Boston, MA

From HCV Advocate :

AASLD 2004

Digestive Disease Week 2004 (DDW 2004)
May 15 - 20, 2004, New Orleans, LA

Selected Highlights from the
39th Annual Meeting of the European Association for the Study of the Liver
(39th EASL)
April 14 - 18, 2004, Berlin Germany
Compiled by Ronald Baker, PhD

http://www.hivandhepatitis.com/2004icr/39easl/main.html

Introduction to New Experimental HCV Therapies Research HepDart 2003 : Information on Viramidine, Infergen plus Actimmune , Albuferon , BILN 2061 , Merimepodib (VX-497) NS5B Polymerase Inhibitors, MN283 and Isatoribine

HCV World News & Research

Conference AASLD Oct 2003

Conference DDW May 2003

Conference European Assoc Mar 2003

Conference: DDW 2002

AASLD Conference 2001